Showing results (321-330 of 447) with videos related to

Sort By:
Pageof 45
Cell Death Discovery|December 28, 2018
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patientsJia-Huan Lu, Zhi-Xiang Zuo, Wei Wang, et al.
Theranostics|February 3, 2025
Erratum: Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression: ErratumDong-Liang Chen, Yun-Xin Lu, Jia-Xing Zhang, et al.
Nature Communications|January 2, 2025
Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting functionJin-Fei Lin, Ze-Xian Liu, Dong-Liang Chen, et al.
Science Bulletin|June 24, 2026
Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistanceYongqiang Zheng, Hui Sun, Zhe Fu, et al.
Nature Communications|October 18, 2019
N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasisRi-Xin Chen, Xin Chen, Liang-Ping Xia, et al.
BMC Cancer|May 18, 2019
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancerFeng Wang, Ming-Ming He, Zi-Xian Wang, et al.
Hepatology (Baltimore, Md.)|March 12, 2014
Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expressionDong-Liang Chen, Zhi-Qiang Wang, Zhao-Lei Zeng, et al.
Nature Communications|October 23, 2023
The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancerJia-Jun Li, Jin-Hong Wang, Tian Tian, et al.
Advances in Therapy|March 13, 2025
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305Markus Moehler, Do-Youn Oh, Ken Kato, et al.
Clinical Colorectal Cancer|December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C StudyManish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.
Pageof 45